Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by gram-positive pathogens

Journal of the Formosan Medical Association

Volumn 103, Issue 5, 2004, Pages 349-354

  Chen, Yao Shen ^a   Lee, Sai Cheong ^b   Kim, Woo Joo ^c  

^a NATIONAL KAOHSIUNG NORMAL UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c Korea University College of Medicine   (South Korea)

Author keywords

Bacterial; Linezolid; Oxazolidinones; Skin diseases; Soft tissue infections; Treatment outcome

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; METICILLIN; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR;

ABDOMINAL PAIN; ADULT; ANEMIA; ANTIMICROBIAL ACTIVITY; ARTICLE; ASIA; BACTERIAL SKIN DISEASE; BACTERIAL VIRULENCE; CANDIDIASIS; CAUCASIAN; CELLULITIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EOSINOPHILIA; ESOPHAGUS HEMORRHAGE; FEMALE; FOLLOW UP; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; NAUSEA AND VOMITING; NONHUMAN; OPEN STUDY; OUTCOMES RESEARCH; PATHOGENESIS; PNEUMONIA; POPULATION RESEARCH; SKIN SURFACE; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; BACTERIAL INFECTION; MICROBIOLOGY; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; SAFETY;

ACETAMIDES; CELLULITIS; CONSUMER PRODUCT SAFETY; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PROTEIN SYNTHESIS INHIBITORS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 3543083367     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Jones ME, Schmitz FJ, Fluit AC, et al: Frequency of occurence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an international surveillance programme. Eur J Clin Microbiol Infect Dis 1999; 18: 403-8.
2. Doern GV, Jones RN, Pfaller MA, et al: Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance program (United States and Canada, 1997). Diagn Microbiol Infect Dis 1999; 34: 65-72.
3. Centers for Disease Control. Straphylococcus aureus resistant to vancomycin - United States, 2002. MMWF 2002; 51: 565-7.
4. Centers for Disease Control. Straphylococcus aureus resistant to vancomycin - Pennsylvania, 2002. MMWR 2002; 51: 902.
5. Henwood CJ, Livermore DM, Johnson AP, et al: Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 2000; 46: 931-40.
6. Gemmell CG: Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 2001; 48: 7-52.
7. Jones RN, Ballow CH, Biedenbach DJ Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn Microbiol Infect Dis 2001; 40:59-66.
8. Perry CM, Jarvis B: Linezolid. A review of its use in the management of serious gram-positive infections. Drugs 2001; 61: 525-51.
9. Stevens DL, Smith LG, Bruss JB, et al, for the Linezolid Skin and Soft Tissue Infectious Study Group: Randomized comparison of linezolid (PNU- 100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-13.
10. Stevens DL, Herr D, Lampiris H, et al: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.
11. Wilcox MH, Dreyden M, Nathwani D: Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections. J Antimicrob Chemother. In press 2004.
12. Li Z, Wilke RJ, Pinto LA, et al: Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21: 263-74.
13. Gerson SL, Kaplan SL, Bruss JB, et al: Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-6.